Рилотумумаб химические свойства, назначение, производство
Описание
Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.
Клиническое использование
A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.
Рилотумумаб препаратная продукция и сырье
сырьё
препарат